Ayala Pharmaceuticals Inc (ADXS)

[foggdogg]

This PR put out April 17th....I just spoke to IR and whomever they are in talks with concerning ADXS11-001, they are still in negotiations with. The back and forth taking place according to IR is that the pps of ADXS keeps going up, therefore Advaxis' management is seeking a deal in proportion to current pps. So the higher the pps, the bigger the licensing deal. IR also mentioned that current leadership has existing close relationships with the likes of Roche and Wyeth. So the potential partner (IMO) is Roche, Wyeth, or GSK. Will be interesting when they announce. ALL IN MY OPINION



Advaxis in Drug Licensing Discussions for Its Flagship Vaccine Construct, ADXS11-001
Advaxis, Inc. (OTCBB: ADXS) is in drug licensing discussions for its flagship vaccine construct, ADXS11-001(formerly named Lovaxin-C), in non-US markets.


Due to the potential materiality of the aforementioned event, Advaxis ' annual general meeting, which was scheduled for Wednesday, April 22, 2009 will be postponed and rescheduled after the licensing contract is completed.


ADXS11-001 is a therapeutic vaccine, like Dendreon’s Provenge, that treats active cancer, but much lower cost because it is not formulated for a specific patient. Unlike currently marketed prophylactic vaccines, ADXS 11-001 treats women who have already developed cervical cancer as a result of human papilloma virus (HPV) infection; the most prevalent sexually transmitted disease in the US today. Advaxis has already filed an IND for a Phase II trial in HPV caused cervical intraepithelial neoplasia (CIN), which is pre-cancerous

http://ih.advfn.com/p.php?pid=nmona&cb=1245078477&article=37355538&symbol=NB%5EADXS